This website will be unavailable from Thursday, May 30, 2024 at 6:00 p.m. through Monday, June 3, 2024 at 7:00 a.m. due to data center maintenance.
Amend CSHB 2292 as follows:
Section 2.12. On page 70, line 13, insert new subsections
(a-1) and (a-2) to read as follows:
(a-1) The commission shall delay requiring a prior
authorization for drugs listed in subsection (b) until the
commission has completed a study evaluating the impact of a
requirement of prior authorization on the recipients of certain
drug classes.
(a-2) Drugs subject to the study in subsection (b) include
drugs used in the treatment of:
(1) cancer and cancer-supportive care,
(2) End-stage Renal Disease,
(3) chronic non-malignant pain,
(4) hemophilia, and
(5) multiple sclerosis.